Multicenter validation study of pathologic response and tumor thickness at the tumor‐normal liver interface as independent predictors of disease‐free survival after preoperative chemotherapy and surgery for colorectal liver metastases
Open Access
Abstract
BACKGROUND To validate pathologic markers of response to preoperative chemotherapy as predictors of disease‐free survival (DFS) after resection of colorectal liver metastases (CLM). METHODS One hundred seventy‐one patients who underwent resection of CLM after preoperative chemotherapy at 4 centers were studied. Pathologic response—defined as the proportion of tumor cells remaining (complete, 0%; major, P = .002, .009), tumor thickness at TNI (P = 0.015, <.001), duration of preoperative chemotherapy (P = .028, .043), number of CLM (P = .038, . 037), and margin (P = .011, .016) were associated with DFS. In a multivariate analysis using both parameters, tumor thickness at TNI (P = .004, .015), duration of preoperative chemotherapy (P = .025), number of nodules (P = .027), and margin (P = .014) were associated with DFS. Tumor size by pathology examination was the predictor of pathologic response. Predictors of tumor thickness at the TNI were tumor size and chemotherapy regimen. There was near perfect agreement for pathologic response (κ = .82) and substantial agreement (κ = .76) for tumor thickness between the central reviewer and local pathologists. CONCLUSIONS Pathologic response and tumor thickness at the TNI are valid predictors of DFS after preoperative chemotherapy and surgery for CLM. Cancer 2013;119:2778–2788. © 2013 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- Pathological Complete Response and Accelerated Drug Approval in Early Breast CancerNew England Journal of Medicine, 2012
- Tumor Thickness at the Tumor-normal Interface: A Novel Pathologic Indicator of Chemotherapy Response in Hepatic Colorectal MetastasesAmerican Journal of Surgical Pathology, 2010
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialThe Lancet Oncology, 2010
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal MetastasesJournal of Clinical Oncology, 2008
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal CancerAnnals of Surgery, 2008
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal CancerJournal of Clinical Oncology, 2005
- Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative ChemoradiotherapyJournal of Clinical Oncology, 2005